TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05333198

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional physical therapy using Epley's maneuver
Description: Epley's maneuver was performed once a week for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oculomotor and Vestibular Ocular Reflex (VOR) exercises
Description: oculomotor and VOR exercises after Epley's maneuver. The exercises were performed for approximately 5 minutes daily or 1 to 2 minutes, 3 to 4 times a day, in sitting position. The exercises were continued for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes. Saccadic exercises were performed by moving eyes between two stationary targets. Smooth pursuit exercises were performed by tracking a moving target while keeping head still and VOR exercises were performed by moving head left to right while maintaining eyes on stationary target
Study: NCT05765916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online mindfulness and acceptance intervention
Description: Session 1 aims to encourage participants to share their experiences; and introduce the purpose, content, delivery mode, duration, and frequency of the intervention.~Session 2 aims to explain how negative illness perceptions lead to fear of cancer recurrence; and introduce the signs, screening, treatment and prognosis of breast cancer, ways to reduce the risk of recurrence, and symptom management.~Session 3 aims to guide the participants to practice body scan and seated meditation.~Session 4 aims to guide the participants to practice detached mindfulness, promoting reflection on the negative effect of indulging in unhelpful thoughts.~In session 5, participants will receive several forms covering work, health, parenting style, intimate relationships, self-development and so on. Participant will be asked to choose one or two forms and set action plans.~In session 6, the facilitator will invite participants to recall positive experiences and practice the Self-care exercise.
Study: NCT05828147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered as two IV infusions of 1000 mg each, given two weeks apart at Day 0 and Week 2. All subjects will receive 40 mg of prednisone orally the night before and morning of each infusion with diphenhydramine and acetaminophen orally thirty to sixty minutes prior to each infusion of rituximab. Subjects will remain on their baseline standard medical regimen.
Study: NCT06250556

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Description: creatine supplementation (Creapure)
Study: NCT06385756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amobarbital
Description: Participants with gynecological laparoscopic surgery who met the trial inclusion criteria were randomly divided into 2 groups. After entering the room, peripheral intravenous infusion was opened and oxygen was absorbed by the mask for 5 L/min. Mean arterial pressure, heart rate and oxygen saturation were routinely monitored. After positioning, the amobarbital-propofol group was given amobarbital sodium 1 mg/kg 1 min before induction, followed by Sufentanil 0.5ug /kg, cisatracurium 0.2mg /kg, penehyclidine hydrochloride 0.01mg /kg, propofol 1.5mg /kg for general anesthesia induction. The propofol group was given the same volume of normal saline 1 min before anesthesia induction, followed by Sufentanil 0.5ug /kg, cisatracurium 0.2mg /kg, penehyclidine hydrochloride 0.01mg /kg, propofol 2.5mg /kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: propofol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: propofol
Study: NCT05809817

Intervention type: PROCEDURE
Intervention: Periodontal treatment
Description: Scaling and root planing
Study: NCT06370468

Intervention type: OTHER
Intervention: Epidemiological investigation
Description: Epidemiological investigation

Intervention type: OTHER
Intervention: Epidemiological investigation
Description: Epidemiological investigation
Study: NCT04781088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05448196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinated Financial Navigation Program
Description: Patients randomized to the intervention arm will be enrolled in a four-month coordinated financial navigation program. This program will take a more proactive, coordinated, and systematic approach and includes concrete action plans, and frequent and standardized follow-ups. All patients randomized to the intervention arm will meet with the nurse navigator (NN) for an intake. The NN will introduce navigation services and navigator's NN role and describe the financial navigation program (e.g., goals and expectations of the financial advocacy and social work programs). Next, the navigator will elicit from the patient their potential and current barriers to completing the diagnostic test or treatment. The navigator will then perform proactive outreach to these resources and coordinate an action plan with the patient.
Study: NCT06514625

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: splint
Description: ready night splints

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: splint
Description: ready night splints

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: splint
Description: ready night splints
Study: NCT04900116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl 0.5 % in 20 ML Injection
Description: In this group, US guided PENG block will be performed with 20 ml 0.5% bupivacaine using a 22 gauge 10 mm block needle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl 0.25 % in 20 ML Injection
Description: In this group, US guided PENG block will be performed with 20 ml 0.25% bupivacaine using a 22 gauge 10 mm block needle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl 0.125 % in 20 ML Injection
Description: In this group, US guided PENG block will be performed with 20 ml 0.125% bupivacaine using a 22 gauge 10 mm block needle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: In this group, US guided PENG block will be performed with 20 ml %0.9 NaCl solution using a 22 gauge 10 mm block needle (Control Group).
Study: NCT05599893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele physical therapy
Description: Before commencing training, warm-up exercises involving upper and lower extremity joint movements were performed for 10 times. During the first and second weeks, the third and fourth weeks, the fifth and sixth weeks and the seventh and eighth weeks, the exercises were performed 10-15, 15-20, 20-25 and 25-30 times per session, respectively. Each session lasted for 10 minutes of warm up, 60 minutes of training and 10 minutes of cool down phase. The participants in the TPG received training four times a week, for 8 weeks, each session lasted for 60 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient educationa and Conventional exercises
Description: They were informed to do their normal daily activities, avoid a sedentary lifestyle, perform regular physical activities such as household activities, maintain a balanced diet and have 6-8 hours of sleep per day.
Study: NCT06201780

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum levels of Janus Kinase 1and 2
Description: assessment of serum levels of Janus Kinase 1and 2 by ELISA

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum levels of Janus Kinase 1and 2
Description: assessment of serum levels of Janus Kinase 1and 2 by ELISA
Study: NCT05517252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele - Yoga
Description: Telehealth interventions with Yoga are called Tele-yoga. Tele-Yoga aims to provide Yoga support to patients at low cost with the same quality and safety as face-to-face

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic Expansion Exercise
Description: Thoracic expansion exercises are deep breathing exercises that focus on inspiration and help to loosen secretions on the lungs. Inspiration is active and usually combined with a three-second, end-inspiratory hold before a passive, relaxed and unforced expiration.
Study: NCT05826574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablets.
Study: NCT04144790

Intervention type: DIETARY_SUPPLEMENT
Intervention: ferrous sulfate
Description: Although established guidelines do not currently exist for iron supplementation for children, studies have demonstrated effectiveness of a 3-month treatment regimen of 5mg/kg per day of orally-administered ferrous sulfate in reducing PLMS and subjective RLS symptoms and in increasing serum ferritin levels. Ferrous sulfate 80 mg/day resulted in improvement of ADHD symptoms in iron-deficient children.
Study: NCT04804384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prehension neuroprosthesis
Description: The experimental condition corresponds to patients in the condition where the prehension neuroprosthesis is active, which means that the extensor muscles of the fingers and thumb will be stimulated by the prehension neuroprosthesis to ensure the opening of the hand. The prehension neuroprosthesis designates a functional electrical stimulation device controlled by the patient which will itself trigger the stimulation of the extensor muscles of the fingers (closed-loop control), according to stimuli which it controls voluntarily. The goal is to restore an opening of the fingers to capture objects.~The control condition corresponds to the patients in the condition where the prehension neuroprosthesis is inactive.
Study: NCT05826574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral capsules.
Study: NCT06459466

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kinesiotherapy exercises with cervical mobilization
Description: Kinesiotherapy Exercises includes Neck stretches , shoulder and upper back mobility, pectoral stretch, cervical isometrics, shoulder blade protraction and retraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kinesiotherapy exercises with cervical mobilization
Description: Kinesiotherapy Exercises includes Neck stretches , shoulder and upper back mobility, pectoral stretch, cervical isometrics, shoulder blade protraction and retraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical Mobilization
Description: This includes Cervical lateral glide mobilization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical Mobilization
Description: This includes Cervical lateral glide mobilization
Study: NCT05786989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selinexor
Description: Given PO
Study: NCT04595383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ti.care
Description: Electronic platform for doctor-patient communication
Study: NCT05397184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryopreserved BE CAR7 T cells (BE752TBCCLCAR7PBL)
Description: Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR7+ T cells/kg BECAR7 Total duration of treatment: 28 days Follow-up: 12 months
Study: NCT05751863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analgesia First Sedation Strategy for Mechanically Ventilated (MV) Trauma Subjects
Description: The Intervention is using a sedation strategy for MV trauma that initially targets pain by intermittent boluses followed by an IV drip only if required. Sedatives are limited to agitation management and for a limited duration as needed. This analgo-sedation approach differs from the approach of using IV drips of analgesics and sedatives simultaneously and discontinuing both once daily to assess subjects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocol Directed Sedation and Daily Sedation Interruption
Description: The active comparator in this study is using a sedation strategy for MV trauma that uses IV drips of analgesics and sedatives simultaneously and discontinues both once daily to assess subjects.
Study: NCT06432894

Intervention type: COMBINATION_PRODUCT
Intervention: Analgesia Nociception Index, remimazolam
Description: The purpose of this study is to determine the validity of ANI in patients undergoing surgery with remifentanil and remimazolam.~During this study, remimazolam infusion rate is determined by the pharmacopoeia.~Remifentanil infusion rate is determined based on the patient's vital signs, systemic status and pain levels. And remifentanil is administrated via targeted infusion control using the Minto model.~ANI scores, vital signs, remifentanil infusion rate are collected at predetermined time points according to the protocol from the start to the end of the surgery.
Study: NCT04633278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: Subjects will receive CMP-001 10mg weekly for 2 doses after which CMP-001 will be administered every 3 weeks. The first dose of CMP-001 may be administered subcutaneously (SC) or Intratumorally (IT) at the discretion of Investigator. All subsequent doses will be injected intratumorally every 3 weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV is administered Q3W.
Study: NCT05866315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Administer remimazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: administer desflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: administer desflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: administer remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: administer remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: administer remifentanil
Study: NCT06432218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video education
Description: A re-watchable video provided before pessary fitting which mainly includes a short introduction of pessary treatment for pelvic organ prolapse, tips and tricks for wearing and self-management of pessary, possible adverse reactions and remedy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional education
Description: Conventional verbal/paper instruction and counseling from a specialized doctor or nurse before pessary fitting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional education
Description: Conventional verbal/paper instruction and counseling from a specialized doctor or nurse before pessary fitting.
Study: NCT06055270

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: All SGBs will be performed by a board-certified anesthesiologist and pain management specialist with extensive experience performing SGBs. The laterality of the SGB will be randomized between the left and right sides of the neck. Participants will be asked to abstain from eating and drinking for 8 hours prior to the SGB. Using ultrasound guidance, the transverse process of the C6 vertebra is identified. Color-doppler is used to identify blood vessels. A 27-gauge needle is used to anesthetize the superficial skin with 1% lidocaine. Then, a 21-gauge ultrasound needle is advanced using an in-plane technique from lateral to medial with careful avoidance of neurovascular structures. After negative aspiration, 8 mL of 1% Lidocaine is deposited beneath the prevertebral fascia and above the Longus coli muscle into the stellate ganglion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo sham injection will be performed in an identical fashion as the stellate ganglion block, with the exception of using 8 mL of 0.9% saline injection instead of Lidocaine
Study: NCT04119115

Intervention type: DEVICE
Intervention: CT-V
Description: CT-V is a newer computed tomography scan which is more comprehensive and tracks movement of the lungs.

Intervention type: DEVICE
Intervention: CT-V
Description: CT-V is a newer computed tomography scan which is more comprehensive and tracks movement of the lungs.

Intervention type: OTHER
Intervention: Metabolites
Description: Metabolites are compounds which can be measured in biospecimens and may indicate a disease or biological process.

Intervention type: OTHER
Intervention: Metabolites
Description: Metabolites are compounds which can be measured in biospecimens and may indicate a disease or biological process.

Intervention type: OTHER
Intervention: Metabolites
Description: Metabolites are compounds which can be measured in biospecimens and may indicate a disease or biological process.
Study: NCT05710237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 25 mg
Description: The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with either risperidone 1 mg or place. It will also be administered in conjunction with supportive therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 25 mg
Description: The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with either risperidone 1 mg or place. It will also be administered in conjunction with supportive therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone 1 MG
Description: The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with either psilocybin 25 mg or placebo. It will also be administered with supportive therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone 1 MG
Description: The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with either psilocybin 25 mg or placebo. It will also be administered with supportive therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo will be administered once during the trial in combination with either risperidone 1 mg or psilocybin 25 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered once during the trial in combination with either risperidone 1 mg or psilocybin 25 mg.
Study: NCT05370638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rounding on discharging patients first
Description: Rounding on discharging patients meant that the attending physician and accompanying team (i.e. if they were working with advanced practice providers or learners) would prioritize seeing any patients that were going to discharge that day. The attending could break protocol if needed for patient care purposes and this was tracked each day.
Study: NCT05856617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Remimazolam besylate anesthesia induction
Study: NCT06486194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted breast milk fortification using preemie device
Description: Mother's breast milk will have additional macronutrient added to it based on analysis with the Preemie device, to ensure it meets current European recommendations for nutrient intakes for preterm infants

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Breast milk fortification
Description: Standard multicomponent breast milk fortifier will be added to mother milk as per usual practice for preterm infants

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Breast milk fortification
Description: Standard multicomponent breast milk fortifier will be added to mother milk as per usual practice for preterm infants
Study: NCT06061796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prone position
Description: patient kept in prone position until the following criteria have been reach for 4 consecutive hours:~* ratio P/F \> 150 mm Hg~* FiO2 \< 60%~* PEEP ≤ 10 cm d'H2O
Study: NCT06337123

Intervention type: DEVICE
Intervention: Device: Physica TT TIbial Plate and Physica Porous KR
Description: Devices: Physica TT Tibial Plate and Physica Porous KR femoral component~Data collection of population that underwent total knee arthroplasty with Physica TT Tibial Plate and Physica Porous KR femoral component

Intervention type: DEVICE
Intervention: Device: Physica TT TIbial Plate and Physica Porous PS
Description: Devices: Physica TT Tibial Plate and Physica Porous KR femoral component~Data collection of population that underwent total knee arthroplasty with Physica TT Tibial Plate and Physica Porous PS femoral component
Study: NCT04782869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Patients will be treated using Starstim 8 device, a device allowing to perform transcranial direct current stimulation. The position of electrodes will be personalized based on the localization of the epileptogenic zone.
Study: NCT04313244

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV Vaccine
Description: 9vHPV intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV Vaccine
Description: 9vHPV intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue Tetravalent Vaccine (TDV)
Description: TDV subcutaneous injection
Study: NCT06373367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Illustration based application
Description: Illustrations regarding the cause, risks, and warning signs of preeclampsia